What Repare Therapeutics does

Repare Therapeutics was a Canadian clinical-stage precision oncology company founded in 2016 and headquartered in Montreal with research operations in Cambridge, UK. The company applied its proprietary SNÅP synthetic lethality platform to identify DNA damage response (DDR) vulnerabilities in cancer cells and develop targeted therapies for genomically defined patient populations. Its clinical pipeline included camonsertib (ATR inhibitor for ATM-deficient tumors, developed under a CRADA with the U.S. National Cancer Institute), RP-3467 (Polθ ATPase inhibitor evaluated in the POLAR Phase 1 trial), RP-1664 (PLK4 inhibitor in the LIONS Phase 1 trial for TRIM37-high solid tumors), and lunresertib (PKMYT1 inhibitor).

The company operated an asset-centric, partnership-driven business model with no commercial product revenue. It generated income by advancing clinical assets through early-stage development and then out-licensing or selling them to larger pharmaceutical partners — notably Gilead Sciences (RP-3467, up to $30 million), Debiopharm (lunresertib worldwide license), and DCx Biotherapeutics (discovery platforms plus retained talent). Following a 25% workforce reduction in September 2024 and a further 75% reduction in February 2025, Repare divested most of its remaining assets and was acquired by XenoTherapeutics, Inc. in January 2026 for approximately $78.2 million plus contingent value rights, resulting in delisting from Nasdaq.

Name

Repare Therapeutics

Legal name

Repare Therapeutics Inc.

Website

https://reparerx.com

Company type

Public

Founded year

2016

Operating status

Acquired

Headcount range

101–250 employees

Short description

Repare Therapeutics was a Canadian clinical-stage precision oncology company that used its proprietary SNÅP synthetic lethality platform to develop DDR inhibitors targeting genetically defined cancer populations, monetizing its pipeline through licensing deals and acquisition rather than commercial product sales.

Ownership category

akta.pro rank

Product category

Precision Oncology Drug Development

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834)

akta.pro primary industry

Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

akta.pro secondary industry

Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA)

Keywords

• Precision oncology drugs
• Synthetic lethality platform
• DNA damage response inhibitors
• Targeted cancer therapy
• Clinical-stage biotechnology

Headquarters

HQ city

Saint Laurent

HQ country

Canada

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations

Revenue model

1. Asset Licensing and Acquisition: Repare generated revenue through licensing agreements and asset sales to pharmaceutical partners. The company sold RP-3467 to Gilead Sciences for up to $30 million ($25M upfront + $5M milestone), licensed lunresertib to Debiopharm, and out-licensed discovery platforms to DCx Biotherapeutics.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Repare Therapeutics developed clinical-stage precision oncology drug candidates using its proprietary SNIPx synthetic lethality platform, which identifies synthetic lethal gene pairs to target DNA damage response vulnerabilities in genetically defined cancer patient populations. The company's pipeline included camonsertib (ATR inhibitor for ATM-deficient tumors), RP-3467 (Polθ ATPase inhibitor), RP-1664 (PLK4 inhibitor for TRIM37-high solid tumors), and lunresertib (PKMYT1 inhibitor). Value was realized through out-licensing clinical assets and discovery platforms to large pharmaceutical partners rather than direct commercialization.

Product overview

Repare Therapeutics was a clinical-stage precision oncology company developing targeted cancer therapies using its proprietary SNÅP synthetic lethality platform. The company's pipeline included multiple clinical-stage drug candidates: camonsertib (ATR inhibitor for ATM-deficient tumors), RP-1664 (PLK4 inhibitor in Phase 1 LIONS trial), and lunresertib (PKMYT1 inhibitor licensed to Debiopharm). Prior to its acquisition by XenoTherapeutics in January 2026, the company sold RP-3467 (Polθ ATPase inhibitor) to Gilead Sciences for up to $30 million and out-licensed its discovery platforms to DCx Biotherapeutics. The company's approach focused on developing therapies that exploit genomic instability in cancer cells while sparing normal cells.

Differentiator

Problem solved

Functional benefit

Products and services

• Camonsertib (RP-3500) An ATR inhibitor designed for the treatment of ATM-deficient tumors through a synthetic lethality mechanism, inhibiting ATR kinase in tumors that lack ATM function. Developed for genetically defined patient populations with DNA repair deficiencies.
• RP-3467 A polymerase theta (Polθ) ATPase inhibitor evaluated in the POLAR Phase 1 clinical trial for safety and preliminary activity alone or in combination with olaparib in patients with various advanced cancers. Acquired by Gilead Sciences in December 2025 for up to $30 million.
• RP-1664 A PLK4 (Polo-like kinase 4) inhibitor evaluated in the Phase 1 LIONS clinical trial for solid tumors with TRIM37-high expression, representing a synthetic lethality approach to tumors with specific genomic alterations.
• Lunresertib (RP-6306) A PKMYT1 inhibitor previously part of Repare's clinical pipeline for gynecologic cancers in combination with camonsertib. Exclusively licensed worldwide to Debiopharm in July 2025.
• SNIPx Synthetic Lethality Discovery Platform Repare's proprietary drug discovery platform for identifying synthetic lethality targets in DNA damage response pathways, enabling the development of precision cancer therapies for genetically defined patient populations. Sold as a standalone offering through out-licensing to DCx Biotherapeutics.

Quantifiable outcome

• 37.5% response rate in Phase 1 MYTHIC trial for lunresertib/camonsertib combination in advanced ovarian cancer
• +1 more outcomes

Named customers3 records

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Five partnerships are on record, tiered core and minor.

• XenoTherapeuticscoreStrategic or Co-development Partner · 28 January 2026XenoTherapeutics, Inc., a Massachusetts-based 501(c)(3) nonprofit biotechnology research foundation focused on xenotransplantation, completed acquisition of Repare Therapeutics through a statutory plan of arrangement. Shareholders received cash payments and contingent value rights, resulting in delisting from Nasdaq and cessation of reporting obligations. Deal valued at approximately $78.2 million plus CVRs.
• Gilead SciencescoreOEM/ Whitelabel/ Licensing Partner · 24 December 2025Gilead Sciences entered into a definitive asset purchase agreement to acquire Repare's Polθ ATPase inhibitor RP-3467 for up to $30 million, including $25 million upfront payment and $5 million upon technology transfer completion. The deal marked Repare's third and most significant portfolio transaction in 2025, with the upfront payment increasing shareholder payout in the pending XenoTherapeutics acquisition.
• DebiopharmcoreOEM/ Whitelabel/ Licensing Partner · 1 August 2025Repare Therapeutics entered into an exclusive worldwide licensing agreement with Debiopharm for lunresertib, continuing the companies' prior collaboration. This partnership followed Repare's portfolio reprioritization and cost reduction initiatives, allowing the company to focus on core clinical assets while enabling lunresertib's continued development.
• DCx BiotherapeuticsminorOEM/ Whitelabel/ Licensing Partner · 4 May 2025Repare Therapeutics announced out-licensing of its discovery platforms to DCx Biotherapeutics, a newly launched company. The transaction included retention of talent and infrastructure from Repare to accelerate development of multi-modal antibody drug conjugates.
• National Cancer Institute (NCI)coreStrategic or Co-development Partner · 15 November 2024Repare Therapeutics announced a CRADA (Cooperative Research and Development Agreement) with the US National Cancer Institute to advance development of camonsertib, an ATR inhibitor for ATM-deficient tumors. The partnership supports ongoing clinical development and provides access to NCI research capabilities and patient populations.

Scale indicators7 records

Recent moves7 records

Expansion highlights3 records

Direct peers

• Tango Therapeutics: Direct synthetic lethality competitor with a precision oncology pipeline targeting DNA damage response and other genetically defined vulnerabilities, using functional genomics screens comparable to Repare's SNIP platform.
• Ideaya Biosciences: Precision oncology biotech developing synthetic lethality and DNA damage response (DDR) therapies, including MAT2A, Polθ, and Werner programs that directly overlap with Repare's mechanism portfolio.
• Black Diamond Therapeutics: Precision oncology company developing targeted therapies based on novel genetic driver mutations in cancer, sharing Repare's biomarker-defined patient stratification approach.
• Foghorn Therapeutics: Precision oncology company leveraging a proprietary chromatin biology platform for target discovery in cancer, comparable to Repare's platform-driven approach to identifying novel oncology targets.
• Relay Therapeutics: Precision oncology company using motion-based computational chemistry to discover drugs against well-validated oncogenic targets — paralleling Repare's genomics-driven discovery model.
• Elevation Oncology: Precision oncology biotech developing biomarker-driven therapies for defined patient populations, sharing Repare's strategic emphasis on genetically selected cancer indications.

Broad incumbents

• Schrödinger: Established computational drug discovery platform serving pharma and running proprietary precision medicine programs, comparable to Repare's platform-led approach but at much broader scale across many therapeutic areas.
• Exscientia: AI-driven drug discovery company with precision oncology and partnered programs, comparable to Repare's technology-enabled precision medicine discovery approach.
• Arcus Biosciences: Clinical-stage oncology company with small-molecule and immuno-oncology programs, overlapping with Repare's clinical-stage cancer drug development focus.
• Mirati Therapeutics: Established precision oncology company (acquired by Bristol Myers Squibb) with targeted cancer therapies including KRAS inhibitors, sharing Repare's biomarker-led oncology strategy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/RepareRx
• LinkedInlinkedin.com/company/repare-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds3 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Repare Therapeutics